TITLE

Dutasteride and Tamsulosin HC1 Capsules (Jalyn)

AUTHOR(S)
Elliott, William T.; Chan, James
PUB. DATE
August 2010
SOURCE
Internal Medicine Alert;8/29/2010, Vol. 32 Issue 16, p126
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers information concerning the approval of the combination of Dutasteride (DUT), a 5-α reductase inhibitor and Tamsulosin (TAM), an α-adrenergic antagonist in a single capsule by the U.S. Food & Drug Administration (FDA).
ACCESSION #
53774514

 

Related Articles

  • New combination.  // Formulary;Oct2009, Vol. 44 Issue 10, p292 

    The article reports that a capsule containing a combination of the drugs morphine and naltrexone was approved by the U.S. Food & Drug Administration on August 13, 2009 for the management of pain. The efficacy of this combination chemotherapy was tested in a placebo-controlled trial in patients...

  • FDA Panel Votes Against Hydrocodone Because of Abuse Potential. Mechcatie, Elizabeth // Neurology Reviews;Jan2013, Vol. 21 Issue 1, p15 

    The article reports that the U.S. Food and Drug Administration (FDA) advisory panelist voted against the approval of Zohydro ER, a capsule formulation of hydrocodone, for the treatment of chronic pain. It informs that the voting was done at the meeting of the FDA's Anesthetic and Analgesic Drug...

  • USFDA nod for Lupin drug.  // Chemical Business;Dec2005, Vol. 19 Issue 12, p45 

    This article reports on an approval received by Lupin Ltd. from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Cephalexin capsules, as of December 2005. The estimate value of the U.S. market for Cephalexin capsules is presented. Other drugs...

  • Zogenix submits new drug application to FDA for chronic pain treatment.  // PharmaWatch: CNS;Jul2012, Vol. 11 Issue 7, p34 

    The article reports that Zogenix Inc. has presented a new drug application (NDA) for Zohydro or hydrocodone bitartrate extended-release capsules to the U.S. Food and Drug Administration (FDA). It says that Zohydro was the investigational product of the company for chronic pain treatment. It says...

  • Pipeline preview.  // Formulary;Feb2008, Vol. 43 Issue 2, p39 

    The article offers news briefs related to drug approvals granted by the U.S. Food and Drug Administration (FDA). One of them is fluvoxamine extended-release capsule, a once-daily treatment for social-anxiety disorder and obsessive-compulsive disorder. Cervarix is a human papillomavirus vaccine...

  • FDA APPROVES FLUVOXAMINE EXTENDED RELEASE FOR TREATMENT OF SAD AND OCD IN ADULTS. Croog, Dena // Primary Psychiatry;Apr2008, Vol. 15 Issue 4, p16 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to approve once daily fluvoxamine maleate extended-release (ER) capsules from Jazz Pharmaceuticals. It says that the drug can be used for the treatment of social anxiety disorder (SAD) and obsessive-compulsive...

  • product showcase.  // Pharmacy Today;Jun2010, Vol. 16 Issue 6, p17 

    The article offers updates on drug approval in the U.S. The Zortress everolimus oral tablets of Novertis AG have been approved by the U.S. Food and Drug Administration (FDA) for the prevention of kidney transplants' organ rejection. The FDA approves Johnson & Johnson's pancrelipase delayed...

  • New doxycycline capsule cleared for rosacea. Belden, Heidi // Drug Topics;7/24/2006, Vol. 150 Issue 14, p14 

    The article reports that the U.S. Food and Drug Administration has approved the Oracea drug from CollaGenex Pharmaceuticals Inc. The drug is intended to treat rosacea. It is a low-dose doxycycline used at subantimicrobial levels in order to capitalize on its anti-inflammatory and antiangiogenic...

  • NEWSLINE.  // Monthly Prescribing Reference;Jul2013, Vol. 29 Issue 7, pA30 

    The article offers news briefs related to the U.S. pharmaceutical industry as of July 2013. The U.S. Food and Drug Administration (FDA) has approved the use of Plan B One-Step, an emergency contraceptive, as a nonprescription product. The FDA has approved the Supplemental New Drug Application...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics